作者
Athira Unnikrishnan, J Peter R Pelletier, Shahla Bari, Marc Zumberg, Abbas Shahmohamadi, Bruce D Spiess, Mary Jane Michael, Neil Harris, Danielle Harrell, Molly W Mandernach
发表日期
2019/6
来源
Transfusion
卷号
59
期号
6
页码范围
1907-1910
出版商
John Wiley & Sons, Inc.
简介
BACKGROUND
Delayed hemolytic transfusion reaction (DHTR) with hyperhemolysis is a potentially fatal complication resulting from alloimmunization that can cause severe hemolysis of both transfused and intrinsic red blood cells (RBCs). Patients with sickle cell disease often receive multiple RBC units during their lifetime and thus are likely to develop alloantibodies that increase the risk for DHTR. Treatment to decrease hemolysis includes intravenous immunoglobulin (IVIG), steroids, eculizumab, rituximab, and plasmapheresis in addition to erythropoietin (EPO), intravenous (IV) iron, vitamin B12, and folate to support erythropoiesis. RBC transfusion is preferably avoided in DHTR due to an increased risk of exacerbating the hemolysis.
CASE REPORT
We report a rare case of anti‐N and anti‐Doa immunoglobulin (Ig)G alloantibody–mediated life‐threatening DHTR with hyperhemolysis in a patient with …
学术搜索中的文章
A Unnikrishnan, JPR Pelletier, S Bari, M Zumberg… - Transfusion, 2019